NOVO NORDISK A S · News & developments
Novo’s Ozempic comparison favors dose escalation—but the evidence is observational
Novo reported a retrospective claims-data analysis in adults with type 2 diabetes taking semaglutide 1 mg. Those who increased to 2 mg were associated with a 6% lower risk of major adverse cardiovascular events than those who switched to tirzepatide, at doses up to 15 mg (adjusted HR 1.06; 95% CI 1.04–1.08; P=0.005). The cardiovascular comparison included 185,705 people who escalated semaglutide and 23,104 who switched. Novo said safety outcomes were not assessed and cautioned that residual confounding could remain; the analysis shows association, not definitive causation.
Why this matters
The result gives Novo a data point for arguing that clinicians need not switch away from Ozempic when considering treatment intensification. That could support staying on Novo’s therapy, but the study design cannot establish that dose escalation caused the lower event rate: treatment choice and patient differences may shape the comparison. It is useful competitive evidence, not a randomized head-to-head verdict, and it leaves safety outside the analysis.
Written with AI from the linked sources and reviewed by a SageNoodle editor. How we work.
Explore NOVO NORDISK A S research →